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and Sudden Cardiac Death in
Hypertrophic Cardiomyopathy
In a recent issue of the Journal, Bruder et al. (1) and O’Hanlon et
al. (2) present 2 studies investigating the association between late
gadolinium enhancement (LGE) by cardiac magnetic resonance in
patients with hypertrophic cardiomyopathy (HCM) and hard
cardiac end points.
Bruder et al. (1) demonstrated a significant and independent
association between the presence of LGE and all-cause and cardiac
mortality, notably with no events occurring among LGE-negatives
during the first 1,825 days of follow-up. O’Hanlon et al. (2), in 217
patients with HCM, reported the association of LGE with major
cardiovascular events and hospital stay, heart failure, and arrhyth-
mic events.
Both studies report a higher albeit nonsignificant incidence of
sudden cardiac death (SCD) in the LGE-positive groups. This is
likely a reflection of the number of patients enrolled, resulting in
the study being underpowered to detect such an association.
Bruder et al. (1) reported 4 cases of SCD, 2 cases of aborted SCD,
and 5 cases of suspected SCD (mean follow-up 1,090 days),
whereas O’Hanlon et al. (2) reported 2 cases of SCD, 2 cases of
ppropriate implantable defibrillator discharge, and 9 cases of
ustained ventricular tachyarrhythmia in 671 patient-years of
ollow-up.
These results suggest that LGE has the potential to become 1
f the main tools for risk stratification in HCM. However, we
hink that some important questions still remain. In the examined
opulations, prevalence of LGE was 67% and 63%, respectively,
hich is in keeping with data from published reports (3). This
high prevalence, however, prohibits the use of the presence of
LGE as a stratification tool alone, because the expected annual
event rates range between 1% and 5%. Although it is clear from the
data presented that LGE-negative patients have a very low risk in
the absence of other clinical risk factors, the presence of LGE
would classify more than 60% of the patients into the high-risk
group, resulting in prophylactic anti-arrhythmic treatment to
prevent a relatively low event rate (4).
Surprisingly, the conventional clinical risk factors were shown to
be very poorly predictive of events. The report by Bruder et al. (1)
demonstrated no association, and nonsustained ventricular tachy-
cardia was the only clinical factor associated with higher risk of
SCD in the paper by O’Hanlon et al. (2). Quantitative parameters
of myocardial fibrosis seem to be better predictors of SCD and
events than the presence of LGE alone, and risk increases
proportionally to the percentage of LGE in the left ventricle.
These results need to be acknowledged and explored further in
future studies. Potentially, parameters such as the relative mass of
LGE, the amount of LV hypertrophy, LV function, and the
presence of ischemia (5), together with clinical factors might allow
better stratification of the risk of patients with LGE. We believe
that cardiac magnetic resonance will probably become the method pof choice of investigation, because it is able to assess all parameters
accurately and noninvasively.
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Reply
We deeply appreciate the interest of Dr. Chiribiri and colleagues in
our paper (1) and welcome their comments.
We completely agree with the authors that prospective data from
large patient populations are needed to finally establish the role of late
gadolinium enhancement (LGE) itself and also of additional param-
eters such as LGEmass, LGE surface area, scar location, and the like
(see Tables 1 to 4 in Bruder et al. [2]) in the clinical routine
management and risk stratification of hypertrophic cardiomyopathy
(HCM) patients. Thus, we have implemented a specific protocol
addressing these points prospectively in the EuroCMR (European
Cardiovascular Magnetic Resonance) registry (3).
The EuroCMR registry is an initiative of the European Society
f Cardiology Working Group on Cardiovascular Magnetic Res-
nance that started to enroll patients in 2007 (2). At present,
pproximately 20,000 patients have been entered into the registry,
ncluding several hundred patients that were enrolled in the
rospective HCM protocol (3). Recently, the first centralized
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March 22, 2011:1400–3clinical follow-up for the HCM protocol was initiated, and we
expect first results in 2011, hoping that these data will help to
answer some of the remaining questions.
Nevertheless, until the remaining questions are answered, we
believe that—on the basis of our data and the results from other
groups demonstrating that LGE is the substrate for ventricular
arrhythmias in HCM (4,5), associated with ventricular remodeling
and heart failure (6) as well as poor outcome (7)—it might be time
to start regarding LGE as a primary risk factor in HCM patients.
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